Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Norton Healthcare

Indication: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non Hodgkin Lymphoma

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Kymera Therapeutics, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.